SCHEMBL24317095

SCHEMBL24317095

CC[C@@H]1CC2(CCCC2)CN1C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19339583 1.00
SCHEMBL19364845 0.96
SCHEMBL21898095 0.92
SCHEMBL20055067 0.92
SCHEMBL18462894 0.78 HDAC6 (0.30)
SCHEMBL21554703 0.76 DPP4 (0.32)
SCHEMBL22943752 0.76 HDAC6 (0.32)
SCHEMBL22944864 0.76 HDAC6 (0.32)
SCHEMBL24754130 0.76
SCHEMBL26724058 0.76 DPP4 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11738013-B2 Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors GILEAD SCIENCES, INC. (US) 2023-08-29 US disclosed
US-20220117952-A1 METHODS FOR TREATING HEPATITIS B VIRUS INFECTIONS USING NS5A, NS5B OR NS3 INHIBITORS GILEAD SCIENCES, INC. 2022-04-21 US disclosed